Near-infrared responsive 5-fluorouracil and indocyanine green loaded MPEG-PCL nanoparticle integrated with dissolvable microneedle for skin cancer therapy.
5-Fluorouracil (5-Fu)
Hyaluronic acid dissolvable microneedle (HA MN)
Indocyanine green (ICG)
Monomethoxy-poly (ethylene glycol)-polycaprolactone (MPEG-PCL)
Skin cancer
Journal
Bioactive materials
ISSN: 2452-199X
Titre abrégé: Bioact Mater
Pays: China
ID NLM: 101685294
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
15
03
2020
revised:
05
04
2020
accepted:
05
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
30
4
2020
Statut:
epublish
Résumé
The prevalence of skin cancer is rising along with the rapid population aging in recent years. Traditional therapies, such as surgical treatment, radiotherapy, chemotherapy, photodynamic therapy, and immunotherapy, may accompany serious side effects, limiting their clinical benefits. According to the biological characteristics of skin cancer, we have already established two kinds of synergetic systems of photothermal therapy (microneedle) and chemotherapy, containing gold nanorods (GNR). Although the microneedle system exhibited great potential for skin cancer treatment, the system could be still improved further. So, we designed a near-infrared light-responsive 5-fluorouracil (5-Fu) and indocyanine green (ICG) loaded monomethoxy-poly (ethylene glycol)-polycaprolactone (MPEG-PCL) nanoparticle (5-Fu-ICG-MPEG-PCL), and then 5-Fu-ICG-MPEG-PCL was integrated with a hyaluronic acid dissolvable microneedle system (HA MN) to get 5-Fu-ICG-MPEG-PCL loaded HA MN for treating skin cancers, including human epidermoid cancer and melanoma. In this system, hyaluronic acid, the microneedle carrier, possesses good skin penetration ability and is approved by FDA as a pharmaceutical adjuvant; 5-Fu is recommended by FDA for skin cancer treatment; ICG, a photothermal agent, possesses a strong photothermal ability and is approved by FDA for its use in the human body. We hypothesized that 5-Fu-ICG-MPEG-PCL could be delivered by the dissolvable microneedle through the skin, and the release behavior of the drug in the nanoparticle could be controlled by near-infrared light for achieving a single-dose cure of skin cancer, improving the cure rate of skin cancer and providing a new idea and possibility for the clinical treatment of skin cancer.
Identifiants
pubmed: 32346657
doi: 10.1016/j.bioactmat.2020.04.002
pii: S2452-199X(20)30054-2
pmc: PMC7176747
doi:
Types de publication
Journal Article
Langues
eng
Pagination
542-552Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Biomaterials. 2020 Apr;237:119827
pubmed: 32036302
Sci Immunol. 2017 Nov 10;2(17):
pubmed: 29127106
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30895944
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Mater Sci Eng C Mater Biol Appl. 2020 Feb;107:110248
pubmed: 31761175
Int J Pharm. 2019 Dec 15;572:118793
pubmed: 31715350
Cancer Res. 2005 Mar 1;65(5):1755-60
pubmed: 15753371
Biophys J. 2014 Sep 16;107(6):L09-12
pubmed: 25229155
Nat Rev Drug Discov. 2019 Mar;18(3):175-196
pubmed: 30622344
Adv Healthc Mater. 2019 Nov;8(22):e1900896
pubmed: 31638739
Nature. 2017 Feb 2;542(7639):115-118
pubmed: 28117445
J Biomed Nanotechnol. 2019 Feb 1;15(2):311-318
pubmed: 30596553
Acta Pharm Sin B. 2019 May;9(3):469-483
pubmed: 31193810
Biomaterials. 2020 Feb;232:119740
pubmed: 31918227
ACS Appl Mater Interfaces. 2017 May 10;9(18):15317-15327
pubmed: 28418236
J Control Release. 2019 Dec 10;315:97-113
pubmed: 31644938
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
J Biomed Nanotechnol. 2019 May 1;15(5):951-965
pubmed: 30890227
J Control Release. 2018 Aug 10;283:151-162
pubmed: 29864476
Small. 2018 Dec;14(49):e1803186
pubmed: 30353663
Small. 2019 Feb;15(6):e1804298
pubmed: 30605244
J Biomed Nanotechnol. 2017 Dec 1;13(12):1581-1597
pubmed: 29490749
Theranostics. 2018 Feb 7;8(6):1558-1574
pubmed: 29556341
ACS Appl Mater Interfaces. 2019 Nov 20;11(46):43588-43598
pubmed: 31651148
Adv Drug Deliv Rev. 2018 Mar 1;127:106-118
pubmed: 29408182
Int J Pharm. 2020 Mar 30;578:119127
pubmed: 32036009